Skip to main content
SpringerLink
Log in
Book cover

Cardiovascular Pharmacology of 5-Hydroxytryptamine pp 407–416Cite as

5-Hydroxytryptamine and migraine

  • Chapter

  • 18 Accesses

Abstract

Migraine is regarded as an episodic syndrome characterised by usually unilateral headache, nausea, vomiting and photophobia, sometimes preceded by certain premonitory aura symptoms. Despite a large number of investigations over the years, the multifactorial pathogenesis of migraine still remains ill understood. However, amongst a host of biogenic substances implicated in the pathophysiology of migraine, none seems to have a better claim than 5-hydroxytryptamine (5-HT) [1–6].

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Lance JW (1982): Mechanism and management of headache . London: Butterworth.

    Google Scholar 

  2. Anthony M (1987): Amine metabolism in migraine, pp. 303–329 in: Blau JN (ed), Migraine, Clinical, therapeutic, conceptual and research aspects . London: Chapman & Hall.

    Google Scholar 

  3. Richardson BP, Engel G, Buchheit K-H, Hoyer D, Kalkman H, Markstein R, Thomson C (1986): Defective serotonergic transmission: A possible cause of migraine and a basis for the efficacy of ergot compounds in the treatment of attacks, pp. 9–21 in: Lance JW (ed), Recent trends in the management of migraine . Aulendorf: Editio Cantor.

    Google Scholar 

  4. Fozard JR (1987): 5-HT: the enigma variations. Trends Pharmacol Sci 8: 501–506.

    Article  CAS  Google Scholar 

  5. Saxena PR (1987): The arteriovenous anastomoses and veins in migraine research, pp. 581–596 in: Blau JN (ed), Migraine – Therapeutic, Conceptual and Research Aspects . Amsterdam: Elsevier.

    Google Scholar 

  6. Raskin NH (1988): Headache, 2nd Ed., New York: Churchill Livingstone.

    Google Scholar 

  7. Sicuteri F, Testi H, Anselmi B (1961): Biochemical investigations in headache: Increase in hydroxyindoleacetic acid excretion during migraine. Int. Arch Allergy 19: 55–58.

    Article  CAS  Google Scholar 

  8. Curran DA, Hinterberger H, Lance JW (1965): Total plams serotonin, 5-hydroxyindole- acetic acid and p-hydroxy-m-methoxy-mandelic acid excretion in normal and migrainous subjects. Brain 88: 997–1010.

    Article  CAS  PubMed  Google Scholar 

  9. Curzon G, Theaker P, Phillips B (1966): Excretion of 5-hydroxyindoleacetic acid (5-HIAA) in migraine. J Neurol Neurosurg Psychiatry 32: 85–90.

    Article  Google Scholar 

  10. Ferrari MD, Odink J, Tapparelli C, Van Kempen MJ, Pennings EJM, Bruyn GW (1989): Serotonin metabolism in migraine. Neurology 39: 1239–1242.

    Article  CAS  PubMed  Google Scholar 

  11. Somerville BW (1965): Platelet-bound and free serotonin levels in jugular and forearm venous blood during migraine. Neurology 26 : 41–45.

    Article  Google Scholar 

  12. Tandon RN, Sur BK, Nath K (1969): Effect of reserpine injections in migrainous and normal control subjects, with estimations of urinary 5-hydroxyindole acetic acid. Neurology 19: 1073–1079.

    Article  CAS  PubMed  Google Scholar 

  13. Del Bene E, Anselmi B, Del Bianco PL, Fanciullacci M, Galli P, Salmon S, Sicuteri F (1977): Fenfluramine headache: a biochemical and monoamine receptorial human study, pp. 101–109 in: Sicuteri F (ed), Headache: New Vistas . Florence: Biomedical press.

    Google Scholar 

  14. Syvalahti E, Kangasniemi P, Ross B (1979): Migraine headache and blood serotonin levels after administration of zimelidine, a selective inhibitor of serotonin uptake. Curr ther Res 25: 299–310.

    Google Scholar 

  15. MacDonald RA (1956): A study of 356 carcinoids of the gastrointestinal tract. A report of four new cases of the carcinoid syndrome. Am J Med 21: 867–878.

    Article  CAS  PubMed  Google Scholar 

  16. Edvinsson L, Denguerce A, Duverger D, MacKenzie ET, Scatton B (1983): Central serotonergic nerves project to the pial vessels of the brain. Nature 306: 55–57.

    Article  CAS  PubMed  Google Scholar 

  17. Dhall U, Cowan T, Haven AJ, Burnstock G (1988): Effect of oestrogen and progesterone on noradrenergic nerves and on nerves showing serotonin-like immunoreactivity in the basilar artery of the rabbit. Brain Res 422: 335–339.

    Article  Google Scholar 

  18. Owman C, Chang J-Y, Hardebo JE (1989): Presence of serotonin in adrenergic nerves of the brain circulation: its role in sympathetic neurotransmission and regulation of cerebral vessel wall. Ch. XVI, This book.

    Google Scholar 

  19. Bradley PB, Engel G, Feniuk W, Fozard JR, Humphrey PPA, Middlemiss DN, Mylecharane EJ, Richardson BP, Saxena PR (1986): Proposals for the classification and nomenclature of functional 5-hydroxytryptamine receptors. Neuropharmacology 25: 563–576.

    Article  CAS  PubMed  Google Scholar 

  20. Humphrey PPA, Feniuk W (1988): Pharmacological characterization of functional neuronal receptors for 5-hydroxytryptamine, pp. 3–19 in: Nobin A, Owman C, Arneklo- Nobin B (eds), Neuronal messengers in vascular function . Amsterdam: Elsevier Science Publication.

    Google Scholar 

  21. Saxena PR, Ferrari M (1989): 5-Hydroxytryptamine1-like receptor agonists and migraine: Possible impact on the pathophysiology of migraine. Trends Pharmacol Sci 10: 200–204.

    Article  CAS  PubMed  Google Scholar 

  22. Fozard JR (1989): 5-HT in migraine: Evidence from 5-HT receptor antagonists for a neuronal aetiology, In press, in: Sandler M (ed), Migraine . London: Oxford University Press.

    Google Scholar 

  23. Loisy C, Beorchia S, Centzone V, Fozard JR, Schechter PJ, Tell GP (1985): Effects on migraine headache of MDL 72222, an antagonist at neuronal 5-HT receptors. Double- blind, placebo-controlled study. Cephalalgia 5:79–82.

    Google Scholar 

  24. Humphrey PPA, Feniuk W, Perren MJ (1989): 5-HT in migraine: evidence with 5-HT1- like receptor agonists for a vascular aetiology, in press in: Sandler M (ed), Migraine . London: Oxford University Press.

    Google Scholar 

  25. Humphrey PPA, Apperley E, Feniuk W, Perren MJ (1989): A rational approach to identifying a fundamentally new drug in the treatment of migraine. Ch. XXXVII, This book.

    Google Scholar 

  26. Saxena PR, Bom AH, Verdouw PD (1989): Characterization of 5-hydroxytryptamine receptors in the cranial vasculature. Cephalalgia 9 (Suppl. 9): 15–22.

    PubMed  Google Scholar 

  27. Saxena PR, Verdouw PD (1982): Redistribution by 5-hydroxytryptamine of carotid arterial blood at the expense of arteriovenous blood flow. J Physiol 332: 501–520.

    CAS  PubMed  Google Scholar 

  28. Bom AH, Verdouw PD, Saxena PR (1989): Carotid haemodynamics in pigs during infusions of 8-OH-DPAT: Reduction in arteriovenous shunting is mediated by 5-hydroxytryptamine1-like receptors. Br J Pharmacol 96: 125–132.

    Article  CAS  PubMed  Google Scholar 

  29. Bom AH, Verdouw PD, Saxena PR (1989): Reduction of cephalic arteriovenous shunting by ergotamine is not mediated by 5-HT1-like or 5-HT2 receptors. Br J Pharmacol 97: 383–390.

    Article  CAS  PubMed  Google Scholar 

  30. Meyer JS, Hata T, Imai A (1987): Evidence supporting a vascular pathogenesis of migraine and cluster headache, pp. 265–302 in: Blau JN (ed), Migraine — Therapeutic, Conceptual and Research Aspects . Amsterdam: Elsevier.

    Google Scholar 

  31. Lauritzen M, Olesen J (1987): Leão’s spreading depression, pp. 387–402 in: Blau JN (ed), Migraine – Therapeutic, Conceptual and Research Aspects , Amsterdam: Elsevier.

    Google Scholar 

  32. Drummond PD, Lance JW (1983): Extracranial vascular changes and the source of pain in migraine headaches. Ann. Neurol 13: 32–37.

    Article  CAS  PubMed  Google Scholar 

  33. Heyck H (1969): Pathogenesis of migraine. Res. Clin. Stud. Headache 2: 1–28.

    Google Scholar 

  34. Sherman JL (1963): Normal arteriovenous anastomoses. Medicine 92: 247–267.

    Google Scholar 

  35. Rowbotham GF, Little E (1965): New concepts on the aetiology and vascularization of meningiomata; the mechanisms of migraine; the chemical process of the cerebrospinal fluid; and the formations of the collections of blood or fluid in the subdural space. Br J Surg 52: 21–24.

    Article  CAS  PubMed  Google Scholar 

  36. Rowbotham GF, Little E (1965): New concepts on the aetiology and vascularization of meningiomata; the mechanisms of migraine; the chemical process of the cerebrospinal fluid; and the formations of the collections of blood or fluid in the subdural space. Br J Surg 52: 21–24.

    Article  CAS  PubMed  Google Scholar 

  37. Brand J, Hadoke M, Perrin VL (1987): Placebo-controlled study of a selective 5-HT1- like agonist, AH25086B, in relief of acute migraine. Cephalalgia 1 (Suppl. 6): 402.

    Google Scholar 

  38. Doenicke A, Brand J, Perrin VL (1988): Possible benefit of GR43175, a novel 5-HT1- like receptor agonist, for the treatment of severe migraine. Lancet 1: 1309–1311.

    Article  CAS  PubMed  Google Scholar 

  39. Perrin VL, Färkkilä M, Goasguen J, Doenicke A, Brand J, Tfelt-Hansen P (1989): Overview of initial clinical studies with intravenous and oral GR43175 in acute migraine. Cephalalgia 9 (Suppl. 9): 63–72.

    PubMed  Google Scholar 

  40. Perrin VL (1985): Clinical pharmacokinetics of ergotamine in migraine and cluster headache. Clin Pharmacokin 10: 334–352.

    Article  CAS  Google Scholar 

  41. Lataste X (1988): 5-HT3 antagonists as antimigraine compounds. Abstract, Int. Congr., Cardiovascular Pharmacology of 5-HT , Oct 4–7, Amsterdam, p. 46.

    Google Scholar 

Download references

Authors
  1. Pramod R. Saxena
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Pharmacology, Erasmus University, Rotterdam, The Netherlands

    P. R. Saxena

  2. Department of Physiology, University of Wales, College of Cardiff, Cardiff, UK

    D. I. Wallis

  3. Department of Pharmacology, Duphar B.V, Weesp, The Netherlands

    W. Wouters  & P. Bevan  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1990 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Saxena, P.R. (1990). 5-Hydroxytryptamine and migraine. In: Saxena, P.R., Wallis, D.I., Wouters, W., Bevan, P. (eds) Cardiovascular Pharmacology of 5-Hydroxytryptamine. Developments in CardioCardiovascular Pharmacology of 5-Hydroxytryptamine, vol 106. Springer, Dordrecht. https://doi.org/10.1007/978-94-009-0479-8_36

Download citation

  • DOI: https://doi.org/10.1007/978-94-009-0479-8_36

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-010-6701-0

  • Online ISBN: 978-94-009-0479-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation